Alessandro Cuomo

Alessandro Cuomo

Auto-generated profile, based on publicly available information

Alessandro Cuomo

Department of Experimental Oncology at IEO, European Institute of Oncology IRCCS , Milan 20139

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in Science
Verified
Journal Article
Open access
SMSara Martin
Sara Martin
SSSimone Scorzoni
Simone Scorzoni
SCSara Cordone
Sara Cordone
AMAlice Mazzagatti
Alice Mazzagatti
GBGalina V Beznoussenko
Galina V Beznoussenko
SSStefano Santaguida
Stefano Santaguida
Chromosomal instability (CIN) generates micronuclei—aberrant extranuclear structures that catalyze the acquisition of complex chromosomal rearrangements present in cancer. Micronuclei are characterized by persistent DNA damage and catastrophic nuclear envelope collapse, which exposes DNA to the cytoplasm. We found that the autophagic receptor p62/SQSTM1 modulates micronuclear stability, influencing chromosome fragmentation and rearrangements. Mechanistically, proximity of micronuclei to mitochondria led to oxidation-driven homo-oligomerization of p62, limiting endosomal sorting complex required for transport (ESCRT)–dependent micronuclear envelope repair by triggering autophagic degradation. We also found that p62 levels correlate with increased chromothripsis across human cancer cell lines and with increased CIN in colorectal tumors. Thus, p62 acts as a regulator of micronuclei and may serve as a prognostic marker for tumors with high CIN.

10 October 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
GGGiovanni Gambi
Giovanni Gambi
GMGabrielle Mengus
Gabrielle Mengus
GDGuillaume Davidson
Guillaume Davidson
EDEwout Demesmaeker
Ewout Demesmaeker
ACAlessandro Cuomo
Alessandro Cuomo
IDIrwin Davidson
Irwin Davidson
Tumor heterogeneity is a key feature of melanomas that hinders development of effective treatments. Aiming to overcome this, we identified LINC00518 (LENOX; lincRNA-enhancer of oxidative phosphorylation) as a melanoma-specific lncRNA expressed in all known melanoma cell states and essential for melanoma survival in vitro and in vivo. Mechanistically, LENOX promoted association of the RAP2C GTPase with mitochondrial fission regulator DRP1, increasing DRP1 S637 phosphorylation, mitochondrial fusion, and oxidative phosphorylation. LENOX expression was upregulated following treatment with MAPK inhibitors, facilitating a metabolic switch from glycolysis to oxidative phosphorylation and conferring resistance to MAPK inhibition. Consequently, combined silencing of LENOX and RAP2C synergized with MAPK inhibitors to eradicate melanoma cells. Melanomas are thus addicted to the lncRNA LENOX, which acts to optimize mitochondrial function during melanoma development and progression. Significance: The lncRNA LENOX is a novel regulator of melanoma metabolism, which can be targeted in conjunction with MAPK inhibitors to eradicate melanoma cells.

1 December 2023 in Science Advances
Verified
Journal Article
Open access
ALAlejandro López-Tobón
Alejandro López-Tobón
RSReinald Shyti
Reinald Shyti
CVCarlo Emanuele Villa
Carlo Emanuele Villa
CCCristina Cheroni
Cristina Cheroni
PFPatricio Fuentes-Bravo
Patricio Fuentes-Bravo
GTGiuseppe Testa
Giuseppe Testa
Copy number variations at 7q11.23 cause neurodevelopmental disorders with shared and opposite manifestations. Deletion causes Williams-Beuren syndrome featuring hypersociability, while duplication causes 7q11.23 microduplication syndrome (7Dup), frequently exhibiting autism spectrum disorder (ASD). Converging evidence indicates GTF2I as key mediator of the cognitive-behavioral phenotypes, yet its role in cortical development and behavioral hallmarks remains largely unknown. We integrated proteomic and transcriptomic profiling of patient-derived cortical organoids, including longitudinally at single-cell resolution, to dissect 7q11.23 dosage–dependent and GTF2I -specific disease mechanisms. We observed dosage-dependent impaired dynamics of neural progenitor proliferation, transcriptional imbalances, and highly specific alterations in neuronal output, leading to precocious excitatory neuron production in 7Dup, which was rescued by restoring physiological GTF2I levels. Transgenic mice with Gtf2i duplication recapitulated progenitor proliferation and neuronal differentiation defects alongside ASD-like behaviors. Consistently, inhibition of lysine demethylase 1 (LSD1), a GTF2I effector, was sufficient to rescue ASD-like phenotypes in transgenic mice, establishing GTF2I -LSD1 axis as a molecular pathway amenable to therapeutic intervention in ASD.

7 November 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
SCSonia Cinque
Sonia Cinque
YVYvessa Verheyden
Yvessa Verheyden
SASara Adnane
Sara Adnane
AMAlessandro Marino
Alessandro Marino
SHSarah Hanache
Sarah Hanache
Eleonora LeucciEleonora Leucci
Eleonora Leucci
Gains of chromosome 12p11.21, encoding for the cancer-specific lncRNA LISRR, correlate with poor survival across different cancers. In melanoma, LISRR is upregulated in immunotherapy-resistant patients to contribute to the generation of drug-tolerant cells by activating an immune-suppressive translational program, affecting the synthesis of PD-L1 and of the glycocalyx. Accordingly, downregulation of LISRR initiates robust immune responses and resensitizes to immunotherapy ex vivo and in vivo. The use of glycans to evade immunity exhibits shared characteristics with the testis, where defects in the glycocalyx cause infertility. Mechanistically, we showed that LISRR affects the ribosome core composition and recruits deleted in azoospermia-associated protein 1 to polysomes to prime the integrated stress response. Our study reveals the contribution of lncRNAs to the generation of cancer-specific ribosomes and identifies an RNA-based strategy to overcome resistance to immune checkpoint blockade.

9 May 2024 in Molecular Systems Biology
Verified
Journal Article
Open access
FGFrancesco Gualdrini
Francesco Gualdrini
SRStefano Rizzieri
Stefano Rizzieri
SPSara Polletti
Sara Polletti
FPFrancesco Pileri
Francesco Pileri
YZYinxiu Zhan
Yinxiu Zhan
GNGioacchino Natoli
Gioacchino Natoli
More than 500 kinases are implicated in the control of most cellular process in mammals, and deregulation of their activity is linked to cancer and inflammatory disorders. 80 clinical kinase inhibitors (CKIs) have been approved for clinical use and hundreds are in various stages of development. However, CKIs inhibit other kinases in addition to the intended target(s), causing both enhanced clinical effects and undesired side effects that are only partially predictable based on in vitro selectivity profiling. Here, we report an integrative approach grounded on the use of chromatin modifications as unbiased, information-rich readouts of the functional effects of CKIs on macrophage activation. This approach exceeded the performance of transcriptome-based approaches and allowed us to identify similarities and differences among CKIs with identical intended targets, to recognize novel CKI specificities and to pinpoint CKIs that may be repurposed to control inflammation, thus supporting the utility of this strategy to improve selection and use of CKIs in clinical settings.

31 March 2023
Verified
Other
Open access
GGGiovanni Gambi
Giovanni Gambi
GMGabrielle Mengus
Gabrielle Mengus
GDGuillaume Davidson
Guillaume Davidson
EDEwout Demesmaeker
Ewout Demesmaeker
ACAlessandro Cuomo
Alessandro Cuomo
IDIrwin Davidson
Irwin Davidson
Tumor heterogeneity is a key feature of melanomas that hinders development of effective treatments. Aiming to overcome this, we identified LINC00518 (LENOX; lincRNA-enhancer of oxidative phosphorylation) as a melanoma-specific lncRNA expressed in all known melanoma cell states and essential for melanoma survival in vitro and in vivo. Mechanistically, LENOX promoted association of the RAP2C GTPase with mitochondrial fission regulator DRP1, increasing DRP1 S637 phosphorylation, mitochondrial fusion, and oxidative phosphorylation. LENOX expression was upregulated following treatment with MAPK inhibitors, facilitating a metabolic switch from glycolysis to oxidative phosphorylation and conferring resistance to MAPK inhibition. Consequently, combined silencing of LENOX and RAP2C synergized with MAPK inhibitors to eradicate melanoma cells. Melanomas are thus addicted to the lncRNA LENOX, which acts to optimize mitochondrial function during melanoma development and progression.Significance:The lncRNA LENOX is a novel regulator of melanoma metabolism, which can be targeted in conjunction with MAPK inhibitors to eradicate melanoma cells.